Search Result

Results for "

Levodopa

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (1) Aryl Hydrocarbon Receptor (1) Dopamine Receptor (11) Drug Metabolite (2) Endogenous Metabolite (7) GABA Receptor (1) Imidazoline Receptor (1) mGluR (2) Monoamine Oxidase (1) nAChR (1) Opioid Receptor (1)
By Research Areas:	Cancer (3) Inflammation/Immunology (1) Neurological Disease (14)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0304

L-DOPA Maximum Cited Publications 19 Publications Verification Levodopa; 3,4-Dihydroxyphenylalanine	Dopamine Receptor Endogenous Metabolite	Neurological Disease Cancer
L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

HY-116016

Etilevodopa L-DOPA ethyl ester; Levodopa ethyl ester	Dopamine Receptor Drug Metabolite	Neurological Disease
Etilevodopa (L-Dopa ethyl ester), an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine .

HY-116016A

Etilevodopa hydrochloride L-DOPA ethyl ester hydrochloride; Levodopa ethyl ester hydrochloride	Dopamine Receptor Drug Metabolite	Neurological Disease
Etilevodopa (L-Dopa ethyl ester) hydrochloride, an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa hydrochloride is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine .

HY-N0304S

*L-DOPA-d6* Levodopa-d₆; 3,4-Dihydroxyphenylalanine-d₆	Dopamine Receptor Endogenous Metabolite	Neurological Disease
L-DOPA-d₆ is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[1][2][3].

HY-W011963

Melevodopa hydrochloride	Dopamine Receptor	Neurological Disease
Melevodopa hydrochloride is an effervescent Levodopa (HY-N0304) prodrug. Levodopa is an orally active metabolic precursor of neurotransmitters dopamine and has anti-allodynic effects and the potential for Parkinson's disease

HY-14859

Dipraglurant ADX48621	mGluR	Neurological Disease
Dipraglurant (ADX48621) is a potent, selective, orally active and brain penetrant mGluR5 negative allosteric modulator (NAM), with an IC₅₀ of 21 nM. Dipraglurant can reduce Levodopa-induced dyskinesia (LID) in vivo . Dipraglurant is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-N0304A

*L-DOPA* sodium** Levodopa sodium; 3,4-Dihydroxyphenylalanine sodium	Dopamine Receptor Endogenous Metabolite	Neurological Disease
L-DOPA (Levodopa) sodium is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA sodium can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA sodium has anti-allodynic effects, and can be used for Parkinson's disease research .

HY-N0304R

*L-DOPA* (Standard)** Levodopa (Standard); 3,4-Dihydroxyphenylalanine (Standard)	Dopamine Receptor Endogenous Metabolite	Neurological Disease Cancer
L-DOPA (Standard) is the analytical standard of L-DOPA. This product is intended for research and analytical applications. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

HY-N0304S1

*L-DOPA-13C6* Levodopa-¹³C₆; 3,4-Dihydroxyphenylalanine-¹³C₆	Dopamine Receptor Endogenous Metabolite	Neurological Disease
L-DOPA- ¹³C₆ is the ¹³C-labled L-DOPA . L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

HY-122278

Melevodopa	Dopamine Receptor	Neurological Disease
Melevodopa is an effervescent levodopa (HY-N0304) prodrug. Levodopa is an orally active metabolic precursor of neurotransmitters dopamine and has anti-allodynic effects and the potential for Parkinson's disease .

HY-B0311D

Carbidopa hydrochloride (S)-(-)-Carbidopa hydrochloride	Aryl Hydrocarbon Receptor	Cancer
Carbidopa hydrochloride ((S)-(-)-Carbidopa hydrochloride) is a drug used to inhibit Parkinson's disease, which has the activity of inhibiting the peripheral metabolism of levodopa. Carbidopa hydrochloride can increase the proportion of peripheral levodopa penetrating the blood-brain barrier, thereby enhancing its effect on the central nervous system. Carbidopa hydrochloride has also been found to be an aryl hydrocarbon receptor (AhR) ligand with anticancer activity, which can inhibit the growth of pancreatic cancer cells and tumors. The selective AhR regulation properties of carbidopa hydrochloride provide potential prospects for its clinical application .

HY-167899

PXT-012253	mGluR	Neurological Disease
PXT-012253 is a positron emission tomography (PET) ligand for mGluR4, as it binds to an allosteric site on mGluR4. PXT-012253 can be utilized in researches related to Parkinson's disease and levodopa-induced dyskinesia .

HY-132392S

*L-DOPA-2,5,6-d3*	Dopamine Receptor Endogenous Metabolite	Neurological Disease
L-DOPA-2,5,6-d₃ is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain[1][2][3].

HY-N0304S2

*L-DOPA-13C* 1 Publications Verification	Dopamine Receptor Endogenous Metabolite	Neurological Disease
L-DOPA- ¹³C is the ¹³C labeled L-DOPA[1]. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[2][3][4].

HY-101392

Harmane 1 Publications Verification	Imidazoline Receptor Monoamine Oxidase Adrenergic Receptor nAChR GABA Receptor Opioid Receptor	Neurological Disease Inflammation/Immunology
Harmane is an inhibitor that binds to benzodiazepine receptors (with an IC₅₀ value of 7 μM), has an IC₅₀ of 24 μM for muscarinic acetylcholine receptors (QNB), an IC₅₀ of 2.8 μM for opioid receptors, and IC₅₀ values of 163 and 101 μM for spironolactone and serotonin, respectively. Harmane is a selective monoamine oxidase inhibitor (with IC₅₀ values of 0.5 μM for MAO A and 5 μM for MAO B). Harman inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing levodopa (L-DOPA)-induced toxicity in PC12 cells. Harmane lowers blood pressure in rats through the I1 imidazoline receptor (I1 receptor) and has antidepressant, anxiolytic, anticonvulsant, and analgesic effects. Harmane enhances the mutagenicity induced by 2-acetylaminofluorene (AAF) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0304

L-DOPA Maximum Cited Publications 19 Publications Verification Levodopa; 3,4-Dihydroxyphenylalanine	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Disease markers Phenols Polyphenols Nervous System Disorder Endogenous metabolite	Dopamine Receptor Endogenous Metabolite
L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

HY-101392

Harmane 1 Publications Verification	Alkaloids Structural Classification other families Source classification Pyridine Alkaloids Plants Indole Alkaloids	Imidazoline Receptor Monoamine Oxidase Adrenergic Receptor nAChR GABA Receptor Opioid Receptor
Harmane is an inhibitor that binds to benzodiazepine receptors (with an IC₅₀ value of 7 μM), has an IC₅₀ of 24 μM for muscarinic acetylcholine receptors (QNB), an IC₅₀ of 2.8 μM for opioid receptors, and IC₅₀ values of 163 and 101 μM for spironolactone and serotonin, respectively. Harmane is a selective monoamine oxidase inhibitor (with IC₅₀ values of 0.5 μM for MAO A and 5 μM for MAO B). Harman inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing levodopa (L-DOPA)-induced toxicity in PC12 cells. Harmane lowers blood pressure in rats through the I1 imidazoline receptor (I1 receptor) and has antidepressant, anxiolytic, anticonvulsant, and analgesic effects. Harmane enhances the mutagenicity induced by 2-acetylaminofluorene (AAF) .

HY-N0304A

*L-DOPA* sodium** Levodopa sodium; 3,4-Dihydroxyphenylalanine sodium	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Phenols Polyphenols Endogenous metabolite Disease Research Fields	Dopamine Receptor Endogenous Metabolite
L-DOPA (Levodopa) sodium is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA sodium can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA sodium has anti-allodynic effects, and can be used for Parkinson's disease research .

HY-N0304R

*L-DOPA* (Standard)** Levodopa (Standard); 3,4-Dihydroxyphenylalanine (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Disease markers Phenols Polyphenols Nervous System Disorder Endogenous metabolite	Dopamine Receptor Endogenous Metabolite
L-DOPA (Standard) is the analytical standard of L-DOPA. This product is intended for research and analytical applications. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

Cat. No.	Product Name	Chemical Structure

HY-N0304S

*L-DOPA-d6*
L-DOPA-d₆ is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[1][2][3].

HY-132392S

*L-DOPA-2,5,6-d3*
L-DOPA-2,5,6-d₃ is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain[1][2][3].

HY-N0304S2

*L-DOPA-13C* 1 Publications Verification
L-DOPA- ¹³C is the ¹³C labeled L-DOPA[1]. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[2][3][4].

HY-N0304S1

*L-DOPA-13C6*
L-DOPA- ¹³C₆ is the ¹³C-labled L-DOPA . L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

Levodopa

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Natural
Products